跳至主要内容
临床试验/EUCTR2007-003628-39-IT
EUCTR2007-003628-39-IT进行中(未招募)不适用

Pilot study to evaluate the local tollerability and efficacy of a new tobramycin 3% nasal spray formulation to reduce the bacterial density of Pseudomonas aeruginosa and/or Staphylococcus aureus, in patients affected by Cystic Fibrosis with rhinosinusal infection - ND

ECUPHARMA S.R.L.0 个研究点开始时间: 2008年4月8日最近更新:

试验速览

阶段
不适用
状态
进行中(未招募)
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • -Documented Cystic Fibrosis diagnosis based on the following: positive sweat test (chloride concentration = 60mEq/l or higher; two CF genotype mutations. -Documented nasal infection by Pseudomonas a. and/or Staphylococcus a. -Forced Expiratory Volume in one second (FEV1) that was at least 50% of the predicted value. - Age (6 to 22 years) -Compliant patients -Informed consent written provided by the patient and/or parent or legal tutor according to the current law.
  • Are the trial subjects under 18? yes
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years) no
  • F.1.3.1 Number of subjects for this age range

排除标准

  • -Hypersensitivity to aminoglycosides -Burkholderia cepacia cronic infection -Pregnancy and lactation -Septal deviation -Current and recurrent epistaxis -Rhinosinusal polypose -Endoscopic nasal surgery during the previous 6 months -Systemic antibiotic administration during the 30 days before the study or during it -Documented periodic or aperiodic allergic rhinitis

研究者

发起方
ECUPHARMA S.R.L.

相似试验